Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 Follow us on ... series of genetic tests that determine individual susceptibility ... disease, Huntington's disease, and Alzheimer's disease. Predictive diagnostics ... and interaction in diseased tissue/cells to understand and ... the response to treatment, such as in the ...
(Date:4/23/2015)... April 23, 2015  Veracyte, Inc. (NASDAQ: VCYT ) ... agreement to sell approximately $40 million of its common ... investors will purchase an aggregate of 4,907,975 shares of ... share, the closing stock price on April 22, 2015. ... investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital ...
(Date:4/23/2015)... PA (PRWEB) April 23, 2015 ... it is the first EMC® Enterprise Content Division ... the entire EMC Documentum® for Life Sciences ... has proven knowledge and capabilities to provide life ... purpose-built solutions. , The EMC Documentum Solution ...
(Date:4/23/2015)... , April 23, 2015  Metanome, Inc., ... announced the company has changed its name to ... Diversigen,s positioning as the single commercial source for ... to capitalize on the diverse opportunities of the ... that Diversigen accepts – including those that are ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Glemser Earns Accreditation for Life Sciences Solution Suite 2Metanome Announces Corporate Name Change to Diversigen 2
... DIEGO, April 3, 2008 Anadys,Pharmaceuticals, Inc. (Nasdaq: ... CanAccord Adams Hepatitis C Conference on Wednesday, April 9, ... is being held at the St.,Regis Hotel in New ... Executive Officer of Anadys,Pharmaceuticals, Inc., will present an overview ...
... BioSpace, the world,s,leading online bioscience job board and ... Career Fair on Thursday, May 1, 2008. The event,will ... am to 4 pm., (Logo: http://www.newscom.com/cgi-bin/prnh/20080222/CLF013LOGO ... will attend the,biotech job fair to meet in person ...
... NEW YORK, April 2, 2008 With their ability ... as part of Big,Pharma,s strategy during lean times, and ... new report from a major life sciences market research,publisher. ... in all types,of pharmaceuticals. This $4.6 billion market has ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference 2Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers 2Excipients Help Pharma Extend Product Life, Profits 2
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... ATLANTA, Ga., April 9, 2012 /PRNewswire-iReach/ ... Inc., is pleased to announce that the company ... Cardiology Update (CCU), presented by the Division of ... April 13-14, 2012. The inaugural meeting will provide ...
... new study by Rice University scientists reveals that plants can use ... The study, which will be published in the April 24 issue ... when plants are touched. "From previous studies, we knew that ... know how these growth changes were activated," said Wassim Chehab, a ...
... Biotechnology Study Center of NYU School of Medicine will ... 2012, to honor three outstanding leaders in biomedical research. ... pure science in the development of pharmaceuticals and honors ... to improving care provided at the patient,s bedside. Recipients ...
Cached Biology News:FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update 2A bit touchy: Plants' insect defenses activated by touch 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 3NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 4NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 5
Donor Goat Serum...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
... [APS 26] to Presenilin 2 Alzheimer's ... of the disease carry mutations in the ... precursor protein (APP). These disease-linked mutations result ... of amyloid-beta (main component of amyloid deposits ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
Biology Products: